Transcatheter valve therapy is a growing treatment option for patients with valvular heart disease. The maturation of transcatheter aortic valve replacement (TAVR) and the rapid adoption of transcatheter mitral and tricuspid therapies have changed the treatment landscape, expanding options for patients with structural heart disease. TVT: The Structural Heart Summit convenes leaders in the field to present three days of world-class education and global networking.
Treatment of structural heart disease is truly multidisciplinary, integrating noninvasive cardiac imaging, surgical therapies, heart failure management, and novel transcatheter approaches — underscoring the importance of professional continuing education.
Tuesday, July 20, 2021
7:00 am - Late-Breaking Clinical Science: Mitral I - Virtual Discussants: David H. Adams,
7:20 AM - Impact of Timing of Surgery on Outcomes of Mitral Valve Surgery After Edge-to-Edge Transcatheter Mitral Repair: Results From The CUTTING-EDGE Registry - Gilbert H. L. Tang, MD
11:45 AM - Heart Team Decision-making: Complex DMR Cases - David H. Adams, MD
12:50 AM - Surgical Intermediate-Risk Barlow’s Disease - David H. Adams, MD
4:50 PM - MITRAL HOT TOPICS #1: The Great Mitral Debates - TEER for Intermediate-Risk DMR: Not Today, Probably Not Tomorrow - David H. Adams, MD